RXi Pharmaceuticals Corp. (NASDAQ: RXII), a discovery-stage biopharmaceutical company, is focused on developing and commercializing proprietary therapeutics, based on RNA interference (RNAi), to treat various human diseases. The company aims to leverage RNAi-based technologies across multiple therapeutic areas to initially treat neurological diseases, metabolic diseases and cancer. For further information, visit the Company’s web site at www.rxipharma.com.
- 17 years ago
QualityStocks
RXi Pharmaceuticals Corp. (NASDAQ: RXII)
Related Post
-
QualityStocksNewsBreaks – Why Micropolis Holding Co. (NYSE American: MCRP) Is ‘One to Watch’
Micropolis (NYSE American: MCRP) is a robotics and AI technology company pioneering the development of unmanned…
-
QualityStocksNewsBreaks – Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Positioned in North America’s Critical Minerals Future
Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) was featured in a recent article that discusses the…
-
QualityStocksNewsBreaks – Copper’s Moment: Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Taps Rising Demand with BC Projects and Custom Mill
Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF), a junior exploration and custom milling company, is poised…